Acurx Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
ACXP$1.060.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Years Ended | ||||||
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| | | | | | | |
| Cash Flow from Operating Activities: · · · · | ||||||
| Net Loss | | $(7,966,538) | | $(14,103,103) | ||
| Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: | | | | | ||
| Share-Based Compensation | | 1,247,401 | | 2,601,903 | ||
| Share-Based Payments to Vendors | | 322,319 | | 833,680 | ||
| (Increase)/Decrease in: | | | | | ||
| Other Receivable | | | 2,710 | | | 78,032 |
| Prepaid Expenses | | 15,105 | | 5,653 | ||
| Accounts Payable and Accrued Expenses | | | (408,779) | | | 200,404 |
| Net Cash Used in Operating Activities | | | (6,787,782) | | | (10,383,431) |
| | | | | | | |
| Cash Flow from Financing Activities: | | | | | ||
| Reverse Stock Split fractional share adjustment | | | (1,040) | | | — |
| Proceeds from Warrant Inducement, net of issuance costs | | | 2,480,553 | | | — |
| Proceeds from Warrant Exercise | | | 1,360,544 | | | 210,199 |
| Proceeds from issuance of common stock in connection with equity line of credit purchase agreement, net of issuance costs | | | 3,808,439 | | | — |
| Proceeds from 2025 March Registered Direct Offering, net of issuance costs | | | 889,420 | | | — |
| Proceeds from 2025 January Registered Direct Offering, net of issuance costs | | | 2,099,253 | | | — |
| Proceeds from At-the-Market Offering, net of issuance costs | | | — | | | 6,405,757 |
| Net Cash Provided by Financing Activities | | | 10,637,169 | | | 6,615,956 |
| Net Increase/(Decrease) in Cash | | 3,849,387 | | (3,767,475) | ||
| Cash at Beginning of Year | | | 3,706,713 | | | 7,474,188 |
| Cash at End of Year | | $7,556,100 | | $3,706,713 | ||
| | | | | | ||
| SUPPLEMENTAL DISCLOSURE OF NON-CASH OPERATING ACTIVITIES | | | | | | |
| Share-Based Compensation to settle accrued compensation (Note 5) | | $413,120 | | $— | ||
| | | | | | | |
| SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES | | | | | | |
| 2025 Equity Line of Credit Purchase Agreement costs (Commitment shares)(Note 4) | | $360,000 | | $— | ||
| 2025 Warrant Inducement Financing costs (Note 4) | | $4,636,869 | | $— | ||
| 2025 January Registered Direct Offering costs (Note 4) | | $85,419 | | $— | ||
| 2025 March Registered Direct Offering costs (Note 4) | | $56,163 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.